stockrowSummit Therapeutics PLC
SMMT Healthcare Biotechnology
Summit Therapeutics PLC’s revenue for fiscal 2022 (year ended December 2022) was $705,000.00.
- EPS
- +63.2%
- Free cash flow
- −112.8%
Quarter to June 2026, against a year earlier
Follow SMMT
Alert me
Summit Therapeutics PLC (SMMT) EPS (diluted)
Summit Therapeutics PLC's EPS (diluted) for fiscal 2025 was −$1.44, compared with −$0.31 in fiscal 2024. Over the twelve months to 30 June 2026 it was −$1.12. Over the past ten years it has ranged from −$2.35 (fiscal 2015) to $0.58 (fiscal 2019); the current reading is higher than 29% of that period. Summit Therapeutics PLC ranks 225th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2025 | −$1.44 | — |
| FY2024 | −$0.31 | — |
| FY2023 | −$0.99 | — |
| FY2022 | −$0.41 | — |
| FY2021 | −$0.67 | — |
| FY2020 | −$0.76 | — |
| FY2019 | −$0.89 | — |
| FY2019 | $0.58 | — |
| FY2018 | −$0.71 | — |
| FY2017 | −$0.41 | — |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | −$0.28 | — |
| Mar 2026 | −$0.24 | — |
| Dec 2025 | −$0.29 | — |
| Sep 2025 | −$0.31 | — |
| 45 more quarters | Free account |
Against its own ten years
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| ASND Ascendis Pharma A/S compare | $12.89 |
| HALO Halozyme Therapeutics, Inc. compare | $3.93 |
| JAZZ Jazz Pharmaceuticals PLC compare | $2.95 |
| TECH Bio-Techne Corp compare | $1.15 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| SMMT Summit Therapeutics PLC | −$1.12 |
| BBIO BridgeBio Pharma, Inc. compare | −$3.04 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
| PCVX Vaxcyte, Inc. compare | −$7.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on SMMT
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement